ISIS-DMPK Rx Extends the Targeting of Antisense Drugs to Include Muscle Tissue
CARLSBAD, Calif., Dec. 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a study for ISIS-DMPKRx in patients with Myotonic Dystrophy Type 1 (DM1). DM1 is a rare genetic neuromuscular disease caused by the production of toxic dystrophia myotonica-protein kinase (DMPK) RNA in cells. ISIS-DMPKRx is specifically designed to reduce toxic DMPK RNA.
Seven-fold lower incidence of VTE in patients treated with ISIS-FXI Rx compared with enoxaparin
Data published in New England Journal of Medicine and featured at the American Society of Hematology annual meeting
Isis to host a webcast at 9:00 a.m. ET on Monday, December 8, 2014
CARLSBAD, Calif., Dec. 7, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today final data from its Phase 2 comparator-controlled study evaluating the incidence of venous thromboembolic e...
CARLSBAD, Calif., Dec. 5, 2014 /PRNewswire/ -- Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), has been awarded the 2014 SCRIP Lifetime Achievement Award, one of the most prestigious of its kind in the pharmaceutical and biotechnology industries worldwide. Dr. Crooke was selected for the lifetime achievement award by an independent panel of global life sciences experts, based on Dr. Crooke's dedication to advancing...
Substantial reductions of up to 86% in triglycerides observed
All patients achieved a triglyceride level <500 mg/dL during study
First study to support the role of apoC-III as a key regulator of triglyceride metabolism utilizing multiple pathways
CARLSBAD, Calif., Dec. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from a Phase 2 study of ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS) were published in The New Engl...
If you are interested in Isis Pharmaceuticals’ investment details, please visit our Investor FAQ page.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Online Investor Kit
Quickly download files right from our Investor Relations Web site.